Author: Abhishek Trigunait

Conversational AI Agents in Pharma & Life Sciences: The Improzo iZO™ Framework

Posted on by Abhishek Trigunait

Introduction

Pharmaceutical and life sciences organizations are entering a new era of digital transformation, with Conversational AI agents at the forefront. These intelligent systems redefine how companies interact with patients, healthcare professionals (HCPs), and internal team-driving efficiency, compliance, and patient-centricity. The Improzo iZO™ framework is purpose-built to deliver secure, compliant, and scalable Conversational AI tailored to the unique needs of life sciences.

What Are Conversational AI Agents?

Conversational AI agents are advanced digital assistants that use natural language processing and machine learning to simulate human conversation. Unlike basic chatbots, they understand context and intent, delivering accurate, human-like responses across text and voice. In pharma and life sciences, these agents automate patient support, streamline clinical trials, and improve HCP communications while integrating securely with existing systems.

4 Key Benefits of Conversational AI in Pharma & Life Sciences

  • Personalized Patient Engagement: AI agents offer tailored support, answer questions, send reminders, and guide patients, building trust and satisfaction.
  • Efficiency and Cost Savings: Automating routine tasks like scheduling and refills reduces staff workload and costs, letting professionals focus on higher-value care.
  • Omnichannel Access: AI agents provide continuous support across web, mobile, SMS, and voice, ensuring help is always available for patients and HCPs.
  • Data-Driven Insights for Decision-Making: Every interaction generates data that can be analyzed to identify trends and patient needs, supporting proactive care and better organizational decisions.

Overcoming Challenges & How Improzo iZO™ Empowers Life Sciences

Integrating Conversational AI in pharma and life sciences comes with hurdles such as regulatory complexity, fragmented data, legacy infrastructure, and user adoption barriers. The Improzo iZO™ framework addresses these challenges through:

  • Seamless Integration: Connects securely with existing platforms for unified data flow.
  • Compliance: Maintains regulatory alignment and protects sensitive information.
  • Transparency & Trust: Offers clear, explainable outputs and escalation paths.
  • User Adoption: Features intuitive design and training to ensure widespread acceptance.

Improzo iZO™ Framework: Built on Proven Capabilities

  • Comprehensive AI Risk Detection: Automated, industry-specific red teaming uncovers vulnerabilities unique to life sciences data and workflows.
  • Real-Time Guardrails: Immediate threat mitigation and content filtering protect against data leaks, hallucinations, and regulatory breaches.
  • Continuous Compliance Monitoring: Automated dashboards track compliance with FDA, EMA, HIPAA, GDPR, and internal policies—reducing manual audit burdens and accelerating innovation.
  • Scalable and User-Friendly: Whether its a single therapy or a global portfolio, Improzo iZO™ scales effortlessly, with intuitive interfaces that drive adoption internally or across patient and HCP.

Conclusion

Conversational AI is reshaping life sciences by streamlining complex workflows and enabling more personalized, accessible, and proactive care.

  • Drives operational excellence and regulatory compliance
  • Enhances patient and HCP engagement through intelligent automation
  • Positions organizations for future innovation and leadership in healthcare

NBA in Pharma: The Playbook for Pharma Companies to transform their operations

Posted on by Abhishek Trigunait

Introduction

Pharma companies are facing a data-driven revolution, with digital innovation and analytics rapidly transforming how they operate and engage with stakeholders. According to a McKinsey report, by 2025, organizations that effectively combine, analyze, and interpret disparate datasets will be best positioned to elevate performance and optimize outcomes for both patients and physicians1. Another McKinsey survey highlights that the winners in this evolving landscape will be those who harness advanced analytics and real-world evidence to inform every interaction and decision.

Challenges in Pharma Operations

Pharma companies are grappling with a rapidly evolving landscape that demands smarter, more agile operations. Here are the key challenges-and what could be done to address them:

  • Fragmented Data Ecosystems:
    Most organizations still operate with data scattered across CRM systems, EHRs, marketing platforms, and external sources. This fragmentation makes it difficult to generate a unified, actionable view of HCPs. By investing in robust data integration and cloud-based platforms, pharma could lay the groundwork for more intelligent engagement.
  • Lack of Personalization and Relevance:
    HCPs are inundated with generic, repetitive communications that fail to address their specific needs or preferences. Companies could deploy advanced analytics and AI-driven content engines to tailor messaging, ensuring each interaction is timely, relevant, and valuable.
  • Inefficient Resource Allocation:
    Sales and medical field teams often spend significant time on administrative tasks or low-value activities, reducing their impact. By adopting AI-powered prioritization and route optimization techniques proven in logistics and retail-pharma could ensure that resources are focused where they matter most.
  • Compliance and Regulatory Complexity:
    With strict regulations governing every interaction, the risk of non-compliance is ever-present. Real-time compliance monitoring and anomaly detection, inspired by financial services and cybersecurity, could help pharma proactively identify and mitigate risks.
  • Siloed Operations and Slow Decision-Making:
    Disconnected teams and manual processes slow down response times and hinder agility. By embracing cross-functional collaboration tools and intelligent automation, companies could accelerate decision-making and adapt faster to market changes.

According to a recent industry study, by 2027, 83% of HCP engagements are expected to be orchestrated by AI-driven NBA platforms. This underscores the urgency for pharma to address these challenges and modernize their operations.

What is Next Best Action?

With HCPs flooded with multiple messages & change in the pharma landscape, a data driven & ML/AI led Next Best Action (NBA) approach is the way ahead. NBA enables the sales & marketing teams to reach HCPs through the right channel, with the right frequency & with correct content. This would increase the promotional impact of the teams, thus enhancing the efficacy of their efforts.

How does Next Best Action work?

NBAs leverage distinct & large amounts of data to recommend individual HCP-centric content & channels based on past interactions. Using advanced analytics, NBA engine identifies patterns & insights to recommend the best channel to reach out to the HCP. Along with the channel recommendation, the engine would also recommend optimal time to send corporate emails & notify field teams using automated platforms. Along with these recommendations, the NBA would also offer rationale for suggested channels, thus instilling confidence into sales & marketing operations.

How can NBA solution help?

  1. Personalized Marketing Content – Moving away from a generalized targeting strategy, NBA leverages advanced analytics & data to identify best action for each HCP target. This personalization aspect would lead to HCPs being more receptive to the marketing activity
  2. Improved coordination – Sales & marketing teams need to work in harmony, rather than working in silos. With the NBA engine, sales teams would be informed of a corporate email or a centralized marketing effort, thus doing away with disorganization & impersonal communication methodology
  3. NBA based HCP Segmentation – HCP segmentation based on NBA recommendations would enable tailored messaging & personalization in communication to HCPs.
  4. Improved RoI – With decreased costs due to optimal marketing & de-duplication of efforts & resulting prescription lift, NBA could go a long way in increasing the RoI of promotional efforts.

The NBA Framework: Crawl, Walk, Run

Pharma companies are increasingly adopting a “Crawl, Walk, run” approach to NBA implementation, ensuring scalable, sustainable transformation while learning from other industries’ best practices.

Crawl: Laying the AI Foundation

  • Pilot Programs:
    Organizations begin with focused NBA pilots in select brands or channels. These pilots use foundational AI models and rule-based recommendations, providing early insights into engagement improvements and operational bottlenecks.
  • Building Unified Data Repositories:
    The initial phase includes integrating prescription, engagement, and third-party data into a single source of truth, reducing manual data prep and enabling more advanced analytics.

Walk: Scaling Intelligent Orchestration

  • Multichannel Integration:
    As capabilities mature, companies expand NBA to multiple brands and channels, integrating digital, in-person, and virtual touchpoints. AI-driven orchestration, inspired by retail and customer service, routes HCPs to the most effective engagement channels.
  • Predictive Analytics:
    Predictive models, like those used in manufacturing and supply chain optimization, anticipate HCP needs and knowledge gaps, triggering timely, personalized outreach.

Run: Enterprise-Wide Autonomy

  • Agentic AI Systems:
    At this stage, companies deploy autonomous AI agents capable of scheduling, personalizing, and optimizing interactions in real time. These systems continuously learn from engagement data and adjust strategies without manual intervention, mirroring advancements in autonomous marketing and customer service.
  • Self-Optimizing Campaigns:
    Drawing from digital advertising best practices, AI reallocates resources across channels based on real-time performance, ensuring optimal ROI and compliance.

The Future Playbook

Pharma companies are not just adopting NBA-they are evolving their operating models by integrating agentic AI and learning from sectors like retail, logistics, and cybersecurity. Hybrid human-AI teams, real-time compliance audits, and quantum-ready analytics are all on the horizon. According to McKinsey, organizations that lead in advanced analytics and digital transformation will set the standard for value and patient outcomes by 2025.1

By following a structured, phased approach and embracing cross-industry innovation, pharma organizations can unlock the full potential of NBA-delivering smarter engagement, improved compliance, and a competitive edge in the digital era.

Boosting Sales Force Effectiveness in Pharmaceuticals: Harnessing the Power of Generative AI

Posted on by Abhishek Trigunait

In the competitive pharmaceutical landscape, enhancing sales force effectiveness is essential for driving commercial success. Generative AI (Gen AI) emerges as a transformative technology that redefines established methodologies, offering innovative solutions to elevate various facets of sales operations. This blog explores how generative AI solutions are differentiated from current approaches, focusing on sales force sizing and placement, customer targeting, territory optimization, call planning, performance measurement, and incentive compensation.

1. Sales Force Sizing and Placement

Current methods for sales force sizing rely heavily on static models, historical averages, or analog-based benchmarks. These approaches often use historical revenue data or workload analysis to determine the number of representatives required in each territory. While these methods provide a starting point, they lack adaptability to real-time market changes or variations in HCP behavior. For example:

Static Revenue Models: Assign resources based on past sales performance without accounting for emerging markets or shifts in demand.

Workload Analysis: Estimates representative needs based on call frequencies and engagement time but fails to incorporate dynamic factors like HCP responsiveness or competitive activity.

Generative AI Advantage:

With Generative AI, it is possible to integrate diverse datasets-historical sales data, market potential, and real-time HCP engagement metrics-to recommend optimal sales force sizes and placements dynamically. Unlike static models, Gen AI based solutions can adapt to changing market conditions by:

  • Continuously analysing demand fluctuations and prescribing patterns.
  • Efficiently simulating multiple scenarios to optimize resource allocation.
  • Preventing over-resourcing in low-potential areas while ensuring adequate coverage in high-growth regions.

2. Targeting the right customers effectively

Traditional customer targeting uses broad segmentation approaches based on limited criteria such as geography, specialty, or prescribing volume. These strategies often fail to capture the nuances of individual HCP preferences or behaviours:

One-Size-Fits-All Segmentation: Treats all HCPs within a segment similarly, missing opportunities for personalized engagement.

Reactive Targeting: Relies on past prescribing data without proactively identifying high-potential customers.

Generative AI Advantage:

Gen AI can enable hyper-personalized targeting by analysing more extensive datasets, including not just prescribing patterns but also digital engagement behaviors, and demographic details.It can help achieve:

  • Predictive Segmentation: Identifying high-potential HCPs likely to respond positively to outreach.
  • Tailored Engagement Plans: Generates specific recommendations for discussion topics, preferred communication channels, and timing-ensuring every interaction is relevant and impactful.

3. Optimizing Territory Alignments

Existing territory design and optimization methodologies are not dynamic enough to effectively adapt to shifts in market dynamics. They also rarely take into consideration inputs such as HCP engagement preferences and access restrictions while identifying total workload.

  • Static Alignments: Territories are rarely reassessed unless triggered by major restructuring.
  • Inefficient Workload Distribution: Leads to overburdened representatives in high-demand areas while underutilizing others in low-demand regions.

Generative AI Advantage:

Gen AI based solutions can help continuously optimize territories by analysing real-time geographic and demographic data alongside market potential. It can ensure:

  • Balanced workloads across representatives at all times.
  • Dynamic adjustments based on HCP engagement trends or competitive activity.
  • Improved coverage of high-priority areas without overextending resources.

4. Streamlining Call Planning

Call planning is often manual or rule-based, relying on rigid frequency targets (e.g., X calls per month per HCP). This approach lacks flexibility and fails to account for individual HCP preferences or availability:

  • Frequency-Based Planning: Focuses on quantity over quality of interactions.
  • Generic messaging: Representatives often approach calls with standard scripts that may not address specific HCP needs.

Generative AI Advantage:

Gen AI can help transform call planning by leveraging historical engagement data and real-time insights:

  • Intelligent Call Scheduling: Recommends optimal call times based on HCP availability and responsiveness patterns.
  • Customized Agendas: Tailors each interaction with relevant product information and discussion points aligned with the HCP’s preferences-fostering deeper connections.

5. Measuring Sales Force Performance

Performance measurement traditionally relies on retrospective metrics such as quarterly sales reports or call activity logs. These lagging indicators provide limited visibility into ongoing trends or emerging issues. Typical challenges faced while measuring performance are:

  • Delayed Insights: Reactive reporting often results in missed opportunities for timely interventions.
  • Narrow Metrics Focus: Emphasizes quantitative KPIs like call volume over qualitative factors like engagement quality.

Generative AI Advantage:

With Gen AI, performance measurement can be enhanced with real-time analytics and predictive modelling:

  • Dynamic Dashboards: Provide real time insights into KPIs such as conversion rates, territory performance, and customer satisfaction.
  • Proactive Interventions: Predictive analytics can identify potential issues early, enabling timely course corrections that improve overall productivity.

6. Enhancing Incentive Compensation Strategies

Established Approaches:

Incentive structures are often based on historical performance metrics without accounting for evolving market conditions or individual preferences:

  • Fixed Compensation Models: There is lack flexibility and personalization in incentive plans with a single plan structure applied to all field force personnels
  • Delayed insights: Sales teams often get delayed insights into their performance, preventing them to take corrective action in time.

Generative AI Advantage:

Gen AI revolutionizes incentive compensation by simulating multiple scenarios using real-time data:

  • Personalized Compensation Plans: With Generative AI, it will be possible to analyse behavioural data to understand motivational drivers of the field and appropriately design IC options to choose from, thus making them more personalized
  • Real time insights and Field Support: Generative AI will enable real time and predictive insights powered by historical data, market trends and customer preferences. This will better equip the field force to gauge the impact of their activity and ensure a successful sales cycle.

Conclusion

Generative AI represents a paradigm shift from traditional methodologies in enhancing sales force effectiveness within the pharmaceutical industry. By addressing the limitations of static models, broad segmentation strategies, and reactive reporting systems, Gen AI introduces precision, adaptability, and scalability into every aspect of sales operations. As we advance further into 2025 and beyond, leveraging generative AI will be critical for maintaining a competitive edge in an increasingly complex marketplace. By integrating real-time data analytics, predictive insights, and personalized engagement strategies at scale, pharmaceutical companies can unlock new levels of efficiency and effectiveness-ultimately driving better outcomes for their organizations and the healthcare providers they serve.

 

Leveraging Next Best Triggers to Transform HCP Engagement in Oncology

Posted on by Abhishek Trigunait

In the dynamic and data-driven field of oncology, effectively engaging healthcare professionals (HCPs) is essential for success. Emerging biopharma companies face unique challenges, including narrow drug labels and complex treatment pathways. To navigate this landscape, Next Best Action (NBA) strategies present a powerful approach, enabling personalized and timely engagement with HCPs. This blog outlines how oncology teams can implement NBA to foster meaningful connections and improve patient outcomes.

Precision Engagement through Contextual Insights

The strength of NBA lies in its ability to deliver tailored interactions based on HCPs’ specific needs, preferences, and clinical contexts. For oncology teams, this means identifying the right oncologists, understanding their treatment priorities, and providing insights that align with their patients’ requirements—all at critical moments in the patient journey.

A Step-by-Step Framework for Implementing NBA in Oncology

  1. Consolidating Data for a Unified View
    The first step in implementing NBA is to gather and integrate data from various sources such as electronic medical records (EMRs), claims data, lab results, and clinical trial databases. By unifying these disparate data sources into a single platform, your team can uncover actionable insights. For instance, identifying oncologists who frequently treat specific cancer types allows you to focus outreach efforts on those most likely to benefit from your therapies.
  2. Identifying High-Impact Triggers
    In the oncology space, triggers often arise from patient journeys or clinical milestones. For example:
    • A newly diagnosed patient may prompt an oncologist to consider first-line therapies.
    • Progression events or biomarker test results could indicate a need for second-line treatments.
      Analyzing these triggers through predictive analytics enables your team to anticipate when an oncologist might require additional information or support, ensuring that your outreach aligns with critical decision-making moments.
  3. Crafting Personalized Content for Oncologists
    With oncologists receiving vast amounts of information daily, your messaging must be relevant and concise:
    • Develop content that addresses specific clinical questions or challenges faced by oncologists treating your target patient population.
    • Use real-world evidence or case studies to demonstrate the efficacy of your therapy in similar clinical scenarios.
    • Tailor delivery channels—such as emails, webinars, or peer-to-peer discussions—based on individual preferences. For instance, an oncologist who frequently attends virtual conferences may respond more positively to webinar invitations than traditional emails.
  4. Leveraging AI-Driven Predictive Analytics
    Artificial intelligence (AI) tools are invaluable for enhancing NBA strategies in oncology. By analyzing historical data and real-time interactions, AI can predict which actions will resonate most with each HCP:
    • Should you prioritize a face-to-face meeting over digital outreach?
    • Is now the right time to share a new study or clinical guideline update?
      AI-driven models continuously refine these recommendations based on feedback loops, ensuring that your engagement strategy evolves alongside HCP needs.
  5. Measuring and Optimizing Engagement
    Oncology marketing teams should adopt a culture of continuous improvement by closely monitoring engagement metrics such as email open rates, content downloads, meeting requests, and shifts in prescribing behavior:
    • Use these insights to identify what’s working and where adjustments are needed.
    • Collaborate with sales and marketing teams to ensure alignment on what constitutes success. For example, if a particular webinar garners high attendance but low follow-up engagement, it may indicate a need for more actionable content or clearer next steps.

Why NBA Matters even more so for Emerging Biopharma

For emerging biopharma companies specializing in oncology therapies, adopting NBA strategies is essential for navigating the complexities of cancer care effectively. The precision required at every interaction with HCPs ensures that resources are focused on high-impact opportunities while building trust through timely and relevant information that supports clinical decisions. This approach not only enhances the likelihood of successful engagements but also ultimately improves patient outcomes by equipping oncologists with the insights they need to make informed treatment choices.

Transforming HCP Engagement through NBA

Implementing NBA in oncology requires commitment but offers significant rewards. By consolidating data into actionable insights, identifying key triggers along the patient journey, crafting personalized content, leveraging AI-driven analytics, and continuously optimizing engagement strategies, your team can transform its interactions with oncologists. In an era where precision medicine is reshaping cancer care, NBA empowers emerging biopharma teams to deliver the right message through the right channel at the right time—creating lasting value for both HCPs and their patients.

Leveraging ‘Predictive  Analytics to support Oncology Patient Journeys’

Posted on by Abhishek Trigunait

The oncology landscape is rapidly changing, with a significant surge in the number of approved therapies. In the past five years alone, 60+ new oncology drugs have been launched, intensifying competition among biopharmaceutical companies to effectively identify and engage specific patient segments that could benefit from these treatments. However, the challenge remains: how can companies accurately pinpoint the right patients at the right time amidst narrow drug labels and small patient populations? To navigate this complexity, it is essential to establish a robust analytics capability that predicts key events in the oncology patient journey. This capability not only assists your sales and marketing teams in targeting oncologists likely to treat eligible patients but also empowers patient support programs to anticipate potential drop-offs and proactively assist those patients. Additionally, it enables medical teams to identify optimal clinical trial sites that align with patient eligibility criteria.

Developing a predictive capability for oncology patient journeys can be structured into four essential steps:

  1. Mapping the Oncology Patient Journey
    The first step involves carefully mapping out the oncology patient journey while prioritizing critical events that impact brand success. For instance, predictive modeling should focus on identifying patients who are transitioning between therapy lines, especially for drugs indicated for first or subsequent lines of treatment. Utilizing established guidelines like those from the National Comprehensive Cancer Network (NCCN) can provide a solid foundation for this mapping process. Engaging internal experts and conducting research within oncology practices will further refine your understanding of patient pathways.
  2. Integrating Real-World Patient Data
    The next step is to acquire and integrate various real-world data sources, such as claims data, electronic medical records (EMR), lab test results, and specialty pharmacy information. A systematic data strategy is crucial for curating and connecting these sources to effectively support predictive modeling capabilities. Your team should evaluate factors such as data richness, granularity, capture rates, refresh rates, acquisition costs, and connectivity with other data sources. Since a single comprehensive patient-level data source may not be available, it may be necessary to make trade-offs across these dimensions while initially developing predictive capabilities using one or two primary data sources.
  3. Developing Predictive Algorithms
    The third step involves creating and testing algorithms designed to predict key events along the oncology journey. Your team can utilize retrospective modeling on real-world data to develop various algorithms while paying close attention to changes in therapy lines across different cancer types. Considerations such as evolving treatment pathways, variability in oncologist practices, and gaps in real-world data must be considered during this process. Collaborating with sales, marketing, and medical teams will enhance algorithm accuracy and foster buy-in for adopting these predictive models. Increasingly, machine learning algorithms are being employed alongside robust feedback mechanisms to create adaptive predictive models that improve over time.
  4. Establishing a Scalable Analytics Platform
    The final step is implementing a scalable analytics platform that facilitates both the development of predictive models and the dissemination of insights to relevant stakeholders. Key features of an effective analytics platform include a comprehensive patient data management module for integrating real-world data sources, an intelligent business rules engine for creating longitudinal patient cohorts with diverse eligibility criteria, an analytics workbench for model development using machine learning techniques, and a business insights consumption module for sharing predictive insights across sales, marketing, patient support, and medical teams.

By strategically combining these four components—mapping the patient journey, integrating real-world data, developing predictive algorithms, and establishing a scalable analytics platform—your biopharma team can significantly enhance its capabilities in predicting oncology patient journeys. Organizations that successfully implement these strategies are likely to receive positive feedback from their field sales teams regarding the timely availability of predictive insights. This capability not only allows sales teams to connect with busy oncologists at critical moments but also ensures that effective therapies reach the right cancer patients when they need them most. In an era where precision medicine is paramount, developing an oncology patient journey prediction capability presents a transformative opportunity for your emerging biopharma team to optimize market strategies and improve patient outcomes.

The Future of Drug Discovery: How Technology is Changing the Game

Posted on by Abhishek Trigunait

Drug discovery is a protracted and resource-intensive endeavor, typically requiring a decade or more and substantial financial investment to bring a single novel therapeutic to market. However, the emergence of innovative technologies presents a transformative potential for accelerating and optimizing this process.

Artificial intelligence (AI) stands as a prominent example, offering powerful capabilities in drug target identification, novel molecule design, and the refinement of drug screening methodologies. Furthermore, AI-driven predictive models are increasingly employed to assess the safety and efficacy of potential drug candidates.

Beyond AI, other cutting-edge technologies significantly impact the drug discovery paradigm. Genomics, the study of the human genome, provides invaluable insights into disease-associated genes, enabling the development of targeted therapies. Similarly, proteomics, the study of proteins, facilitates the identification of disease-relevant protein targets for therapeutic intervention.

Single-cell analysis, a revolutionary technique, allows for the in-depth characterization of individual cells, enabling the identification of rare cell populations implicated in disease pathogenesis and the development of targeted therapies for these elusive subpopulations.

These advancements collectively signify a paradigm shift in drug discovery. By leveraging these emerging technologies, researchers can expedite the discovery process, enhance the efficiency of drug development pipelines, and ultimately expand the therapeutic armamentarium for previously intractable diseases. The future of drug discovery holds immense promise, with these technological innovations poised to revolutionize healthcare and improve the lives of countless individuals.”